Author:
Curtis Helen J,Inglesby Peter,Morton Caroline E,MacKenna Brian,Green Amelia,Hulme William,Walker Alex J,Morley Jessica,Mehrkar Amir,Bacon Seb,Hickman George,Bates Chris,Croker Richard,Evans David,Ward Tom,Cockburn Jonathan,Davy Simon,Bhaskaran Krishnan,Schultze Anna,Rentsch Christopher T,Williamson Elizabeth J,Rowan Anna,Fisher Louis,McDonald Helen I,Tomlinson Laurie,Mathur Rohini,Drysdale Henry,Eggo Rosalind M,Wing Kevin,Wong Angel YS,Forbes Harriet,Parry John,Hester Frank,Harper Sam,O’Hanlon Shaun,Eavis Alex,Jarvis Richard,Avramov Dima,Griffiths Paul,Fowles Aaron,Parkes Nasreen,Douglas Ian J,Evans Stephen JW,Smeeth Liam,Goldacre Ben,
Abstract
BackgroundOn 8 December 2020 NHS England administered the first COVID-19 vaccination.AimTo describe trends and variation in vaccine coverage in different clinical and demographic groups in the first 100 days of the vaccine rollout.Design and settingWith the approval of NHS England, a cohort study was conducted of 57.9 million patient records in general practice in England, in situ and within the infrastructure of the electronic health record software vendors EMIS and TPP using OpenSAFELY.MethodVaccine coverage across various subgroups of Joint Committee on Vaccination and Immunisation (JCVI) priority cohorts is described.ResultsA total of 20 852 692 patients (36.0%) received a vaccine between 8 December 2020 and 17 March 2021. Of patients aged ≥80 years not in a care home (JCVI group 2) 94.7% received a vaccine, but with substantial variation by ethnicity (White 96.2%, Black 68.3%) and deprivation (least deprived 96.6%, most deprived 90.7%). Patients with pre-existing medical conditions were more likely to be vaccinated with two exceptions: severe mental illness (89.5%) and learning disability (91.4%). There were 275 205 vaccine recipients who were identified as care home residents (JCVI group 1; 91.2% coverage). By 17 March, 1 257 914 (6.0%) recipients had a second dose.ConclusionThe NHS rapidly delivered mass vaccination. In this study a data-monitoring framework was deployed using publicly auditable methods and a secure in situ processing model, using linked but pseudonymised patient-level NHS data for 57.9 million patients. Targeted activity may be needed to address lower vaccination coverage observed among certain key groups.
Publisher
Royal College of General Practitioners
Reference40 articles.
1. World Health Organization (2019) Ten threats to global health in 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 (accessed 14 Oct 2021).
2. World Health Organization (2021) COVID-19 vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed 14 Oct 2021).
3. Department of Health and Social Care (2020) Oxford University/AstraZeneca vaccine authorised by UK medicines regulator. https://www.gov.uk/government/news/oxford-universityastrazeneca-vaccine-authorised-by-uk-medicines-regulator (accessed 14 Oct 2021).
4. Medicines and Healthcare products Regulatory Agency (2021) Moderna vaccine becomes third COVID-19 vaccine approved by UK regulator. https://www.gov.uk/government/news/moderna-vaccine-becomes-third-covid-19-vaccine-approved-by-uk-regulator (accessed 14 Oct 2021).
5. Public Health England (2020) COVID-19: the green book, chapter 14a. https://web.archive.org/web/20210102111105/https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948757/Greenbook_chapter_14a_v4.pdf (accessed 21 Oct 2021).